SPOTLIGHT: Alpharma licenses rights to NSAID patch

in deal with Institut Biochimique
Alpharma has struck a deal with Institut Biochimique for the exclusive license and distribution rights to market the Flector Patch, the first prescription topical NSAID patch approved by the FDA in the United States. Release

Suggested Articles

Insitro picked up $143 million to build out its technology, pursue new targets and advance treatments for genetically defined patient groups.

Generation Bio filed for a $215 million IPO to advance a pair of gene therapies for liver disease and push one of them into the clinic.

The IPO will push Avidity's lead muscle disorder program through IND-enabling studies and into the clinic in 2021.